TherapeuticsMD TXMD
NASDAQ TXMD
$1.88 -0.01 (-0.79%)
As of: Oct 22, 2026 · 10:45 AM EDT

TherapeuticsMD (TXMD) Short-Term Debt repayments (2013)

Updated

TherapeuticsMD's Short-Term Debt repayments was $81.66 million in FY2019.

Analysis

TherapeuticsMD (TXMD) Short-Term Debt repayments (2013) Analysis & Trends

  • The FY2019 figure marks the lowest annual Short-Term Debt repayments since FY2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,175.94 Bn 1,144.53 Bn 19.71 Bn -
2 Johnson & Johnson 638.47 Bn 556.99 Bn 17.26 Bn 6.45 Bn
3 AbbVie 504.39 Bn 477.51 Bn 12.70 Bn -
4 Merck 377.60 Bn 331.98 Bn 12.21 Bn -
5 Novartis Ag 304.31 Bn 268.30 Bn 11.24 Bn -
6 Astrazeneca 267.64 Bn 241.32 Bn 12.86 Bn -
7 Amgen 242.06 Bn 197.45 Bn 7.24 Bn -
8 Gilead Sciences 193.83 Bn 168.03 Bn 6.22 Bn -
9 Pfizer 172.62 Bn 119.27 Bn 10.94 Bn -
10 TherapeuticsMD 21.82 Mn 21.82 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2013 100,000.00
Mar 31, 2013 400,000.00
API Access

TherapeuticsMD Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=TXMD&period=max&api_key=YOUR_API_KEY